Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 834 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Courageous children receive Star Awards in virtual celebration December 17, 2021 FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma November 13, 2024 New ESMO Local and Locoregional Prostate Cancer Living Guideline v1.0 February 19, 2026 FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Load more HOT NEWS How can we improve LGBTQ+ cancer care? – That Cancer Conversation Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... 9 Ways to Use Social Media for Support Throughout Your Cancer...
